Otsuka Pharmaceutical Co., Ltd. announces that it has received regulatory approval in Japan for an orally-disintegrating-dose (OD) form of REXULTI^® (brexpiprazole) tablets.

REXULTI^® OD 0.5 mg, 1 mg, and 2 mg tablets will now become available in addition to the already available regular tablets in 1mg and 2mg doses. REXULTI^® OD Tablets are a dose form that quickly disintegrate in the oral cavity so that it is easy to take for patients who cannot take the tablet due to difficulty in swallowing.

Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT_1A and dopamine D₂ receptors, and an antagonist at 5-HT_2A and noradrenaline alpha_1B/2C receptors.

It received manufacturing and marketing approval in Japan for the indication of schizophrenia in 2018.